Targeting the JAK2–STAT3–UCHL3–ENO1 axis suppresses glycolysis and enhances the sensitivity to 5-FU chemotherapy in TP53-mutant colorectal cancer
aDepartment of General Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
bState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
cHebei Key Laboratory of Etiology Tracing and Individualized Diagnosis and Treatment for Digestive System Carcinoma, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
dDepartment of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
eThe Second Department of General Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
fDepartment of General Surgery, the Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
gResearch Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China
* Corresponding authors.
收起